Clinical Trial Update: MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating MnSOD as an esophageal protectant to reduce esophagitis during radiation/chemotherapy for non-small cell lung cancer; the study st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Toxicity
• Non-small Cell Lung Cancer

Drugs mentioned

• MnSOD (manganese superoxide dismutase)

Snippet

Sponsor: Joel Greenberger | Conditions: Esophageal, Toxicity | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-11-12